Transformable vesicles for cancer immunotherapy

Shuang Wang; Xiaoming Hu; Wei Wei; Guanghui Ma

doi:10.1016/j.addr.2021.113905

Transformable vesicles for cancer immunotherapy

Adv Drug Deliv Rev. 2021 Dec:179:113905. doi: 10.1016/j.addr.2021.113905. Epub 2021 Jul 29.

Authors

Shuang Wang¹, Xiaoming Hu², Wei Wei³, Guanghui Ma⁴

Affiliations

¹ State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, No. 1 Bei-Er-Tiao, Zhong Guan Cun, Beijing 100190, PR China.
² State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, No. 1 Bei-Er-Tiao, Zhong Guan Cun, Beijing 100190, PR China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, PR China.
³ State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, No. 1 Bei-Er-Tiao, Zhong Guan Cun, Beijing 100190, PR China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, PR China. Electronic address: weiwei@ipe.ac.cn.
⁴ State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, No. 1 Bei-Er-Tiao, Zhong Guan Cun, Beijing 100190, PR China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, PR China. Electronic address: ghma@ipe.ac.cn.

PMID: 34331988
DOI: 10.1016/j.addr.2021.113905

Abstract

Immunotherapy that utilizes the human immune system to fight cancer represents a revolutionary method for cancer treatment. Immunotherapeutic agents that trigger the immune response should be carefully delivered to the desired site to maximize immunotherapy effectiveness and minimize side effects. Vesicles offer the possibility of encapsulating both hydrophilic and hydrophobic drugs and thus serve as a promising delivery tool. As multiple irreconcilable requirements exist at different transport stages, developing vesicles transformable in response to given stimuli is of great significance. In this review, we first introduced various vesicle types used for immunotherapy. Furthermore, the typical stimuli that trigger vesicle transformation and the usually generated transformation styles were described. Focusing on three aspects of antigen-presenting cell (APC)/T cell activation, tumor microenvironment (TME) amelioration, and immunogenic cell death (ICD)-induced immunotherapy, we reviewed recently reported transformable vesicles for tumor treatment. Finally, we put forward possible directions for future research and clinical translation.

Keywords: Cancer immunotherapy; Immune activation; Immunogenic cell death; Stimuli-sensitive; Transformation; Tumor microenvironment; Vesicles.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antigen-Presenting Cells / drug effects
Antineoplastic Agents, Immunological / administration & dosage*
Antineoplastic Agents, Immunological / pharmacology*
Chemistry, Pharmaceutical
Drug Delivery Systems / methods*
Humans
Immunogenic Cell Death / drug effects*
T-Lymphocytes / drug effects
Tumor Microenvironment / drug effects*

Substances

Antineoplastic Agents, Immunological